Epstein Secrets

m pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing anti-malaria drugs. 6) Making human genetic disease models in organoids and aging reversal using CRISPR

e Genetics $200,000 Cold-resistant elephants $2,500,000 2nd tranche $10,000,000 Total 1) Thirty genomes collected so far on a small budget by James Clement. $200K would get 8% ownership of the company and allow another 30 genomes to be collected, sequenced and therapies patented. 2) Using CRISPR to e

m pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing anti-malaria drugs. 6) Making human genetic disease models in organoids and aging reversal using CRISPR

d-resistant elephants $2,500,000 2nd tranchc $10,000,000 Total 1) Supercentenarianstudv.com Thirty genomes collected so far on a small budget by James Clement. $200K would get 8% ownership of the company and allow another 30 genomes to be collected, sequenced and therapies patented. 2) eGenesisBio.com: U

m pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing anti-malaria drugs. 6) Making human genetic disease models in organoids and aging reversal using CRISPR

netics Cold-resistant elephants 2nd tranche $10,000,000 Total I ) Supercentenarianstudv.com Thirty genomes collected so far on a small budget by James Clement. $200K would get 8% ownership of the company and allow another 30 genomes to be collected, sequenced and therapies patented. 2) eGenesisBio.com: U

m pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing anti-malaria drugs. 6) Making human genetic disease models in organoids and aging reversal using CRISPR

logy Space Genetics Cold-resistant elephants 2nd tranche Total 1) Supercentenarianstudv.com Thirty genomes collected so far on a small budget by James Clement. $200K would get 8% ownership of the company and allow another 30 genomes to be collected, sequenced and therapies patented. 2) eGenesisBio.com: U